EMILIN1

Across TCGA pan-cancer cohorts, EMILIN1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EMILIN1 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EMILIN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EMILIN1 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where EMILIN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	35	view →
LUAD	OS	Median	III,IV	0.213	0.684	.004	30	view →
PDAC	DFS	Quartile	All	0.229	0.480	<.001	27	view →
LSCC	DFS	Median	All	0.613	0.802	.011	6	view →
GBM	DFS	Tertile	All	0.739	0.847	.033	4	view →
HNSC	OS	Tertile	IV	0.633	0.836	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EMILIN1–CCRCC (DFS)

Open the CCRCC breakdown →